Zevacor Molecular (Zevacor), manufacturer and distributor of positron emission tomography (PET) and single photon emission computed tomography (SPECT) radiopharmaceuticals, announced the arrival of a 70 MeV Cyclotron at its new production facility in Noblesville, Indiana.
Westinghouse Electric Company and NorthStar Medical Radioisotopes announced a memorandum of understanding to explore producing medical radioisotopes from the core of commercial nuclear reactors, and methods of global distribution. The exploration involves generating the most widely used radioisotope in medical diagnostic imaging by treating an isotope of the chemical element molybdenum rather than enriched uranium.
September, 11, 2015 – Japanese medical vendor Nipro Corp. signed a definitive agreement to acquire Infraredx Inc., maker ...
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
The cardiovascular service line, whether existing within the confines of an acute-care environment or outpatient setting ...
For any cardiology department looking to upgrade or replace its cardiovascular information system (CVIS), the main ...
Two key requirements for today’s cardiovascular information systems (CVIS) are solid integrations with both enterprise ...
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
Sunshine Heart Inc. announced commencement of a new study examining the impact of the C-Pulse system on pulmonary circulation and right heart related to pulmonary hypertension and heart failure.
AliveCor Inc. announced significant milestones related to patients with atrial fibrillation (AFib) using the AliveCor Mobile ECG. Since receiving the first U.S. Food and Drug Administration (FDA) clearance for the AF Detector, an algorithm to detect atrial fibrillation in an ECG (electrocardiogram), 30 percent of AliveCor patients have received an AFib detection.
The Carillon mitral contour system is projected to be a cost-effective treatment option when compared to a typical regimen of optimal medical treatment (OMT), the present standard of care for functional mitral regurgitation (FMR).
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
Researchers at Thomas Jefferson University showed that a simple questionnaire, evaluation and pulse-oximetry monitoring can lead to early detection of sleep apnea in patients hospitalized for congestive heart failure (CHF).
St. Jude Medical Inc. announced that five-year results from the FAME trial have confirmed the long-term benefits of fractional flow reserve (FFR) in guiding percutaneous coronary intervention (PCI) over angiography alone.
September 9, 2015 — The U.S. Food and Drug Administration (FDA) granted 510(k) for Philips Healthcare’s Spectral ...
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
St. Jude Medical Inc. announced primary results from the LEADLESS II study that confirm the positive benefits of the Nanostim leadless pacemaker for patients in need of a single-chamber ventricular pacemaker.
SRI International and DataSpeaks Inc. announced that SRI has licensed the Science of Individuality Measurement Algorithm (SIMA) software from DataSpeaks. SRI will integrate SIMA into the development of a secure enterprise system for clinical decision-making.
Sunshine Heart Inc. announced the U.S. Food and Drug Administration (FDA) has approved an amendment to the stopping rule criteria for the company's COUNTER HF pivotal study for its C-Pulse Heart Assist System. The agency has agreed to change this protocol from "all cause" deaths to specifically, mortality associated with device, procedure or therapy.